C3 Activation Products, C3 Containing Immune Complexes, the Terminal Complement Complex and Native C9 in Patients with Rheumatoid Arthritis

References

• Ruddy S. Plasma protein effectors of inflammation: complement, Textbook of Rheumatology.Second Edition., WN Kelley, Jr, ED Harris, S Ruddy, CB Sledge. WB Saunders, Philadelphia 1985; 83–94
   Google Scholar
• Mollnes T E, Lea T, Tschopp J. Activation-dependent epitopes in the terminal complement pathway. Complement Inflamm 1989; 6: 223–35
   PubMedGoogle Scholar
• Mollnes T E, Lea T, Mellbye O J, Pahle J, Grand O, Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum 1986; 29: 715–21
   PubMedGoogle Scholar
• Mollnes T E, Paus A. complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 1359–64
   PubMedGoogle Scholar
• Sanders M E, Kopicky J A, Wigley F M, Shin M L, Frank M M, Joiner KA. Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. J Rheumatol 1986; 13: 1028–34
   PubMed Web of Science ®Google Scholar
• Ropes M W, Bennet G A, Cobb S, Jacox R, Jessar RA. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175–6
   PubMedGoogle Scholar
• Mollnes T E, Carred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1989; 73: 484–8
   Web of Science ®Google Scholar
• Garred P, Mollnes T E, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329–35
   PubMed Web of Science ®Google Scholar
• Mollnes T E, Lea T, Frølund S S, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197–202
   PubMed Web of Science ®Google Scholar
• Brandslund I, Siersted H C, Svehag S E, Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J Immunol Methods 1981; 44: 63–71
   PubMed Web of Science ®Google Scholar
• Mollnes T E, Tschopp J. A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9. J Immunol Methods 1987; 100: 215–21
   PubMed Web of Science ®Google Scholar
• Amlot PL. Neopitopes expressed by immune complexes. Complement Inflamm 1989; 6: 236–48
   PubMedGoogle Scholar
• Garred P, Mollnes T E, Lea T, Lachmann PJ. Enzyme immunoassay detection of circulating immune complexes by monoclonal antibodies to C3 neoepitopes with special reference to IgG concentration and to interfering anti-immunoglobulin antibodies. J Immunol Methods 1989; 117: 59–66
   PubMed Web of Science ®Google Scholar
• Brown B W, Hollander M. Statistics: A. Biomedical Introduction. John Wiley and Sons., New York 1977; 292–340
   Google Scholar
• Montgomery DC. Design and unaivsis of experiments.Second edition. John Wiley and Sons., New York 1948; 59–70
   Google Scholar
• Garred P, Mollnes T E, Kazatchkine MD. Activation-dependent antigenic changes of human C3. Complement Inflamm 1989; 6: 205–18
   PubMedGoogle Scholar
• Berkowicz A, Kappelgaard L, Petersen J, Nielsen H, Ingemann-Hansen T, Halkjâr-Kristensen J, Sørensen H. Complement C3c and C3d in plasma and synovial fluid in rheumatoid arthritis. Acta Pathol Microbiol Immunol Scand C 1983; 91: 397–102
   PubMedGoogle Scholar
• Charlesworth J A, Gwyn Williams D, Sherington E, Lachmann P J, Peters DK. Metabolic studies of the third compoment of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest 1974; 53: 1578–87
   PubMed Web of Science ®Google Scholar
• Brandslund I, Teisner B, Hyltoft Petersen P, Svehag SE. Development and clinical application of electroimmunoassays for direct quantification of the complement C3 split products C3c and C3d. Scand J Clin Lab Invest. Suppl. 1984; 168: 57–71
   PubMedGoogle Scholar
• Folkersen J, Tiesner B, Eggertsen G, Sim RB. Immunoblotting analysis of the peptide chain structure of the physiological breakdown products of the third component of human complement. Electrophoresis 1986; 7: 379–86
   Web of Science ®Google Scholar
• McDuffie FC. Immune complexes in the rheumatic disease. J Allergy Clin Immunol 1978; 62: 37–43
   PubMed Web of Science ®Google Scholar
• Aguado M T, Lambris J D, Tsokos G C, Burger R, Bitter-Suermann D, Tamerius J D, Dixon F JI, Heofilopoulos AN. Monoclonal antibodies against complement C3 neoantigens for detection of immune complexes and complement activation. J Clin Invest 1985; 76: 1418–26
   PubMed Web of Science ®Google Scholar
• Rumfeld W R, Morgan B P, Campbell AK. The ninth complement component in rheumatoid arthritis, Behcet's disease and other rheumatic diseases. Br. J Rheumatol 1986; 25: 266–70
   PubMedGoogle Scholar
• Ruddy S, Everson L K, Schur P H, Austen KF. Hemolytic assay of the ninth complement component: Elevation and depletion in rheumatic diseases. J Exp Med 1971; 134: 259–75
   PubMed Web of Science ®Google Scholar
• Mollnes T E, Abrahamsen T G, Garred P. Alterations in the terminal complement pathway in leukopenic children with malignant diseases during episodes with evidence of infection. Complement Inflamm 1989; 6: 460–9
   PubMedGoogle Scholar